The Efficacy And Safety Of Lacidipine And Amlodipine Once-Daily Treatment In Hypertensive Adult Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The sustained reduction in elevated blood pressure and lower incidence of adverse events of Lacidipine may provide additional benefits for hypertension patients than other CCBs (calcium channel blockers). This study is to compare the efficacy and safety of Lacidipine with Amlodipine, the most widely used CCB in Taiwan, in hypertensive patients.
Condition or disease
Drug: Lacidipine 4 or 6 mg (oral)Drug: Amlodipine 5 or 10 mg(oral)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
40 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Informed consent written prior to the recruit into the study
Male or female subjects
Patients with diagnosis of essential, uncomplicated hypertension
After one to two weeks washout period, patients showing, systolic blood pressure equal or lager than 160mmHg or diastolic blood pressure equal or lager than 90mmHg
Subject could be enrolled in one of the following state:
Patients previously untreated for hypertension;
Intolerant or not responding to their current therapy;
Patients controlled under their previous therapy but who can safely and agree to be switched to the trial therapy could clinically feasible for mono-therapy for hypertension control.
Any form of secondary hypertension
History of malignant hypertension or evidence of accelerated hypertension
Myocardial infarction within 3 months
Unstable angina pectoris
Congestive heart failure
Life threatening arrhythmia
History of cerebrovascular accident
Clinically relevant renal disease; defines if serum creatinine equal or lager than 1.5 mg/dl
Liver function abnormal: glutamic-oxalacetic transaminase lager than 2 times of upper limit normal or glutamic-pyruvic transaminase lager than 2 times of upper limit normal
Existence of any serious systemic disease
Allergic history to the compounds of both study medication
Can not comply the study protocol or misunderstand the informed consent form
Other diseases which treated by calcium channel blockers